$ENTX News

Correction: Entera to Participate in Upcoming Fall Investor Conferences

Entera to Participate in Upcoming Fall Investor Conferences

Entera Bio Files Prospectus For Resale Of Up To 134,803,910 Ordinary Shares By Selling Shareholders From July Private Placement

Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation

Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA Agreement

Entera Bio shares slip as Q2 loss comes in wider than expected

Entera Bio (NASDAQ:ENTX) Slides on Wider Q2 Loss Despite FDA Phase 3 Alignment and $275M Cash Raise

Entera Announces Second Quarter 2026 Financial Results and Business Updates

Entera Bio Intends To File Ind For EB612 In First Half Of 2027; EB613 Phase 3 Study Initiation Planned For Late 2026, Topline Data Anticipated In Second Half 2028

Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting

Entera Bio Announces That Post-Hoc Data From Its Phase 2 Clinical Trial Of EB613Has Been Selected For Two Presentations At The American Society For Bone And Mineral Research Annual Meeting

Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference

Entera Bio Rebounds As Investors Balance Phase 3 Funding Against Dilution Risk

Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement

Entera Bio Enters Into Securities Purchase Agreement For Oversubscribed Private Placement Financing, Expected To Result In Aggregate Gross Proceeds Of ~$275M

Entera Bio Announces FDA Has Provided Positive Feedback On The Phase 3 Protocol For EB613, The Company's Oral Osteoporosis Tablet

ENTX Stock On Track For Best Day In Over 5 Years — What’s Driving The Rally?

Reported Earlier: Entera Bio Receives FDA's Positive Feedback For Its Phase 3 Registrational Protocol For EB613 Tablet In Development To Treat Osteoporosis

Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis

Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026